Pharma BD Deal Intelligence
One durable niche orphan drug (Procysbi) justified a fraction of the price; the rest of what was paid for (Quinsair, Raptor's pipeline) evaporated within a year or two of close.
Full analysis, sources & comparables →Fierce Biotech flagged that while the deal expanded Horizon's rare-disease franchise, Raptor's pipeline had suffered repeated clinical failures (notably the…
Pharmacy Times framed the deal as accelerating Horizon's transformation into a rare-disease specialist, with Procysbi adding a long-tail patent-protected…
The patient foundation that funded early Procysbi research criticized post-acquisition pricing — the drug launched at ~$300K/yr in 2013 and reached >$1M/yr for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Horizon Pharma agreed to acquire Raptor Pharmaceutical for $9.00/share cash (~$800M equity, ~$860.8M total including debt repayment). Adds PROCYSBI (cysteamine for nephropathic cystinosis) and QUINSAIR (inhaled levofloxacin for CF, EU only) to Horizon's rare-disease portfolio. Closed October 25, 2016.
One durable niche orphan drug (Procysbi) justified a fraction of the price; the rest of what was paid for (Quinsair, Raptor's pipeline) evaporated within a year or two of close.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Horizon Pharma plc / Raptor Pharmaceutical Corp. (this deal) | 2016 | $860M | 46 |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
← Browse all deals · How we score deals
More: 2016 deals · Horizon Pharma plc deals · Infectious Disease deals